NEW YORK – Nanomix said Tuesday it forged an agreement with Gepa to distribute Nanomix's handheld eLab electrochemical analyzer and assays in Italy.
San Leandro, California-based Nanomix said the deal with Gepa, an Italian distributor and supplier of diagnostic products, will expand the reach of Nanomix's technology in the fight against sepsis. Nanomix announced earlier this month a five-country distribution deal with the Mast Group, which followed other commercial agreements earlier this year for distribution in Israel and the Middle East in preparation of instrument and assay launches.
Financial and other terms of the deal were not disclosed.
John Hardesky, chief commercial officer for Nanomix, said in a statement that Gepa has extensive experience in the market for diagnostics against critical infections, sepsis, and antibiotic-resistant infections. Nanomix's eLab system is a portable handheld immunoassay and chemistry instrument.
"Over the last decade, their team has actively implemented clinical diagnostic solutions to help caregivers improve patient outcomes and positively impact hospital performance," he said. "We are excited to support and align with Gepa on an ambitious execution plan to bring our technology to a competitive market like Italy."
Nanomix said sepsis affects upward of 50 million people each year, leading to about 11 million deaths.